{"id":282,"date":"2019-12-08T22:34:10","date_gmt":"2019-12-08T22:34:10","guid":{"rendered":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/6-11-antilipemics\/"},"modified":"2025-01-16T22:27:16","modified_gmt":"2025-01-16T22:27:16","slug":"6-11-antilipemics","status":"publish","type":"chapter","link":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/6-11-antilipemics\/","title":{"raw":"6.11 Antilipemics","rendered":"6.11 Antilipemics"},"content":{"raw":"Antilipemic agents reduce hyperlipidemia that may lead to additional health problems such as stroke, myocardial infarction, angina, and heart failure. Medications should be used in adjunct with a healthy diet and exercise regime approved by the client<\/span>\u2019s health care provider.\n

<\/a>Atorvastatin<\/h2>\nMechanism of Action: <\/strong>Atorvastatin inhibits HMG-CoA reductase and cholesterol synthesis, which reduces low-density lipoprotein (LDL).\n\nIndications: <\/strong>This medication is used for hyperlipidemia and the prevention of cardiovascular disease.\n\nNursing Considerations: <\/strong>Do not use with client<\/span>s who have hepatic disease.\n\nThis medication is contraindicated with client<\/span>s who are pregnant or breastfeeding. Do not give to client<\/span>s under 10 years of age.\n\nUse caution with elderly client<\/span>s due to increased risk for myopathy.\n\nSide Effects\/Adverse Effects: <\/strong>A health care provider will assess routine liver function for a client<\/span> taking atorvastatin. Nausea, diarrhea, dyspepsia, increase in blood glucose, rhabdomyolysis, myalgia, or muscle spasms may be produced by taking this medication. Rhabdomyolysis is a condition in which damaged skeletal muscle breaks down rapidly, causing muscle pain and weakness. Some of the muscle breakdown products are harmful to the kidneys and can cause kidney failure. There may be tea-colored urine or an irregular heartbeat with rhabdomyolysis.[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\nHealth Teaching & Health Promotion: <\/strong>Client<\/span>s should take the prescribed medication as directed and avoid consuming grapefruit juice during drug therapy. The medication should be used with dietary modifications. If the client<\/span> experiences muscle pain, tenderness, or weakness, these should be reported to the health care provider.[footnote]uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<\/sup>\n\nNow let's take a closer look at the medication grid on atrovastatin in Table 6.11a.[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\nTable 6.11a Atorvastatin Medication Grid\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/td>\nPrototype\/G<\/strong>eneric<\/strong><\/td>\nNursing <\/strong>Considerations<\/strong><\/td>\nTherapeutic Effects<\/strong><\/td>\nSide\/Adverse Effects<\/strong><\/td>\n<\/tr>\n
HMG-CoA Reductase Inhibitor<\/strong><\/td>\natorvastatin<\/a>\n\n <\/td>\nTake at the same time each day, with or without food\n\nReport muscle weakness, feeling tired, abdominal pain, or yellowing of skin or eyes\n\nClient<\/span>s who are pregnant or breastfeeding should not take this medication<\/td>\nReduce LDL<\/td>\nRhabdomyolysis, myalgia, and muscle spasms\n\nAbnormal liver enzymes\n\nMay increase blood glucose\n\nNausea, diarrhea, and dyspepsia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/a>Ezetimibe<\/h2>\nMechanism of Action: <\/strong>Ezetimibe blocks the absorption of cholesterol in the small intestines to reduce LDL.\n\nIndications: <\/strong>This medication is used for treatment of hyperlipidemia and familial hypercholesterolemia.\n\nNursing Considerations: <\/strong>If medication is combined with HMG-CoA reductase inhibitors, do not give to pregnant or breastfeeding client<\/span>s.\n\nSide Effects\/Adverse Effects: <\/strong>Use with caution when ezetimibe is combined with additional medication. Client<\/span>s may experience arthralgia, rhabdomyolysis, hepatic impairment, dizziness, upper respiratory infections, or diarrhea if they are taking this medication. Minimal side effects were reported with monotherapy.[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\nHealth Teaching & Health Promotion: <\/strong>Client<\/span>s should take the prescribed medication as directed and avoid consuming grapefruit juice during drug therapy. The medication should be used with dietary modifications. If the client<\/span> experiences muscle pain, tenderness, or weakness, this should be reported to the health care provider.[footnote]uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<\/sup>\n\nNow let's take a closer look at the medication grid for ezetimibe in Table 6.11b.[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\nTable 6.11b Ezetimibe Medication Grid\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/td>\nPrototype\/G<\/strong>eneric<\/strong><\/td>\nNursing <\/strong>Considerations<\/strong><\/td>\nTherapeutic Effects<\/strong><\/td>\nSide\/Adverse Effects<\/strong><\/td>\n<\/tr>\n
Cholesterol Absorption Inhibitor<\/strong><\/td>\nezetimibe<\/a><\/td>\nTake at the same time each day, with or without food\n\nReport muscle weakness, feeling tired, abdominal pain, or yellowing of skin or eyes<\/td>\nReduce LDL<\/td>\nArthralgia and rhabdomyolysis\n\nHepatic impairment\n\nDizziness\n\nUpper respiratory infection\n\nDiarrhea<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cholestyramine<\/h2>\nMechanism of Action:<\/strong> Cholestyramine works by binding to bile acids in the intestines, preventing their reabsorption, and promoting their excretion in the feces.\n\nIndications:<\/strong> Bile acid sequestrants are given to reduce the amount of bile acids available for the body to use in producing cholesterol, leading to a decrease in cholesterol levels.\n\nNursing Considerations: <\/strong>Monitor the client<\/span>'s lipid profile, liver function tests, and vitamin levels. These medications should not be used in client<\/span>s with a history of bowel obstruction or in client<\/span>s with triglyceride levels greater than 500 mg\/dL.\n\nSide Effects\/Adverse Effects:<\/strong> Adverse effects of bile acid sequestrants include constipation, bloating, flatulence, and abdominal discomfort.\n\nHealth Teaching & Health Promotion: <\/strong>Client<\/span>s should be advised to increase their fluid and fiber intake to alleviate these symptoms. These medications can also interfere with the absorption of fat-soluble vitamins, so client<\/span>s should be advised to take supplements as prescribed.\n\nNow let\u2019s take a closer look at the medication grid for cholestyramine in Table 6.11c.\n\nTable 6.11c Cholestyramine Medication Grid[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/th>\nPrototype\/G<\/strong>eneric<\/strong><\/th>\nNursing <\/strong>Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Bile Acid Sequestrant<\/strong><\/td>\ncholestyramine<\/a><\/td>\nMonitor the client<\/span>'s lipid profile, liver function tests, and vitamin levels\n\nThese medications should not be used in client<\/span>s with a history of bowel obstruction or in client<\/span>s with triglyceride levels greater than 500 mg\/dL<\/td>\nReduce LDL<\/td>\nConstipation\n\nBloating\n\nFlatulence\n\nAbdominal discomfort<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Niacin<\/h2>\nMechanism of Action: <\/strong>Niacin works by inhibiting the synthesis of triglycerides and LDL cholesterol.\n\nIndications:<\/strong> Niacin is given to reduce the production of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol, while increasing the levels of high-density lipoprotein (HDL) cholesterol in the blood.\n\nNursing Considerations: <\/strong>Nursing considerations for administration include monitoring lipid profiles, liver function tests, and blood glucose levels. Client<\/span>s should be advised to take niacin with meals to minimize adverse effects. Client<\/span>s should also be advised to report any adverse effects to their health care provider.\n\nSide Effects\/Adverse Effects: <\/strong>Adverse effects of niacin include flushing, itching, and tingling, particularly in the face, neck, and chest.\n\nHealth Teaching & Health Promotion: <\/strong>Client<\/span>s should also be advised to avoid hot beverages or alcohol, as these can exacerbate flushing. Niacin can also cause liver toxicity, so liver function tests should be monitored regularly. In addition, niacin can increase blood glucose levels, so client<\/span>s with diabetes should have their blood glucose levels monitored closely. Client<\/span>s should be advised to take niacin with meals to minimize adverse effects.\n\nNow let\u2019s take a closer look at the medication grid for niacin in Table 6.11d.\n\nTable 6.11d Niacin Medication Grid[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote]<\/sup>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/th>\nPrototype\/G<\/strong>eneric<\/strong><\/th>\nNursing <\/strong>Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Vitamin B3<\/strong><\/td>\nniacin<\/a><\/td>\nMonitor lipid profiles, liver function tests, and blood glucose levels\n\nTake niacin with meals to minimize adverse effects\n\nReport any adverse effects to their health care provider<\/td>\nReduce LDL<\/td>\nConstipation\n\nBloating\n\nFlatulence\n\nAbdominal discomfort<\/td>\n<\/tr>\n<\/tbody>\n<\/table>","rendered":"

Antilipemic agents reduce hyperlipidemia that may lead to additional health problems such as stroke, myocardial infarction, angina, and heart failure. Medications should be used in adjunct with a healthy diet and exercise regime approved by the client<\/span>\u2019s health care provider.<\/p>\n

<\/a>Atorvastatin<\/h2>\n

Mechanism of Action: <\/strong>Atorvastatin inhibits HMG-CoA reductase and cholesterol synthesis, which reduces low-density lipoprotein (LDL).<\/p>\n

Indications: <\/strong>This medication is used for hyperlipidemia and the prevention of cardiovascular disease.<\/p>\n

Nursing Considerations: <\/strong>Do not use with client<\/span>s who have hepatic disease.<\/p>\n

This medication is contraindicated with client<\/span>s who are pregnant or breastfeeding. Do not give to client<\/span>s under 10 years of age.<\/p>\n

Use caution with elderly client<\/span>s due to increased risk for myopathy.<\/p>\n

Side Effects\/Adverse Effects: <\/strong>A health care provider will assess routine liver function for a client<\/span> taking atorvastatin. Nausea, diarrhea, dyspepsia, increase in blood glucose, rhabdomyolysis, myalgia, or muscle spasms may be produced by taking this medication. Rhabdomyolysis is a condition in which damaged skeletal muscle breaks down rapidly, causing muscle pain and weakness. Some of the muscle breakdown products are harmful to the kidneys and can cause kidney failure. There may be tea-colored urine or an irregular heartbeat with rhabdomyolysis.[1]<\/sup><\/a><\/sup><\/p>\n

Health Teaching & Health Promotion: <\/strong>Client<\/span>s should take the prescribed medication as directed and avoid consuming grapefruit juice during drug therapy. The medication should be used with dietary modifications. If the client<\/span> experiences muscle pain, tenderness, or weakness, these should be reported to the health care provider.[2]<\/sup><\/a><\/sup><\/p>\n

Now let’s take a closer look at the medication grid on atrovastatin in Table 6.11a.[3]<\/sup><\/a><\/sup><\/p>\n

Table 6.11a Atorvastatin Medication Grid<\/p>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/td>\nPrototype\/G<\/strong>eneric<\/strong><\/td>\nNursing <\/strong>Considerations<\/strong><\/td>\nTherapeutic Effects<\/strong><\/td>\nSide\/Adverse Effects<\/strong><\/td>\n<\/tr>\n
HMG-CoA Reductase Inhibitor<\/strong><\/td>\natorvastatin<\/a><\/p>\n

 <\/td>\n

Take at the same time each day, with or without food<\/p>\n

Report muscle weakness, feeling tired, abdominal pain, or yellowing of skin or eyes<\/p>\n

Client<\/span>s who are pregnant or breastfeeding should not take this medication<\/td>\n

Reduce LDL<\/td>\nRhabdomyolysis, myalgia, and muscle spasms<\/p>\n

Abnormal liver enzymes<\/p>\n

May increase blood glucose<\/p>\n

Nausea, diarrhea, and dyspepsia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/a>Ezetimibe<\/h2>\n

Mechanism of Action: <\/strong>Ezetimibe blocks the absorption of cholesterol in the small intestines to reduce LDL.<\/p>\n

Indications: <\/strong>This medication is used for treatment of hyperlipidemia and familial hypercholesterolemia.<\/p>\n

Nursing Considerations: <\/strong>If medication is combined with HMG-CoA reductase inhibitors, do not give to pregnant or breastfeeding client<\/span>s.<\/p>\n

Side Effects\/Adverse Effects: <\/strong>Use with caution when ezetimibe is combined with additional medication. Client<\/span>s may experience arthralgia, rhabdomyolysis, hepatic impairment, dizziness, upper respiratory infections, or diarrhea if they are taking this medication. Minimal side effects were reported with monotherapy.[4]<\/sup><\/a><\/sup><\/p>\n

Health Teaching & Health Promotion: <\/strong>Client<\/span>s should take the prescribed medication as directed and avoid consuming grapefruit juice during drug therapy. The medication should be used with dietary modifications. If the client<\/span> experiences muscle pain, tenderness, or weakness, this should be reported to the health care provider.[5]<\/sup><\/a><\/sup><\/p>\n

Now let’s take a closer look at the medication grid for ezetimibe in Table 6.11b.[6]<\/sup><\/a><\/sup><\/p>\n

Table 6.11b Ezetimibe Medication Grid<\/p>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/td>\nPrototype\/G<\/strong>eneric<\/strong><\/td>\nNursing <\/strong>Considerations<\/strong><\/td>\nTherapeutic Effects<\/strong><\/td>\nSide\/Adverse Effects<\/strong><\/td>\n<\/tr>\n
Cholesterol Absorption Inhibitor<\/strong><\/td>\nezetimibe<\/a><\/td>\nTake at the same time each day, with or without food<\/p>\n

Report muscle weakness, feeling tired, abdominal pain, or yellowing of skin or eyes<\/td>\n

Reduce LDL<\/td>\nArthralgia and rhabdomyolysis<\/p>\n

Hepatic impairment<\/p>\n

Dizziness<\/p>\n

Upper respiratory infection<\/p>\n

Diarrhea<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cholestyramine<\/h2>\n

Mechanism of Action:<\/strong> Cholestyramine works by binding to bile acids in the intestines, preventing their reabsorption, and promoting their excretion in the feces.<\/p>\n

Indications:<\/strong> Bile acid sequestrants are given to reduce the amount of bile acids available for the body to use in producing cholesterol, leading to a decrease in cholesterol levels.<\/p>\n

Nursing Considerations: <\/strong>Monitor the client<\/span>‘s lipid profile, liver function tests, and vitamin levels. These medications should not be used in client<\/span>s with a history of bowel obstruction or in client<\/span>s with triglyceride levels greater than 500 mg\/dL.<\/p>\n

Side Effects\/Adverse Effects:<\/strong> Adverse effects of bile acid sequestrants include constipation, bloating, flatulence, and abdominal discomfort.<\/p>\n

Health Teaching & Health Promotion: <\/strong>Client<\/span>s should be advised to increase their fluid and fiber intake to alleviate these symptoms. These medications can also interfere with the absorption of fat-soluble vitamins, so client<\/span>s should be advised to take supplements as prescribed.<\/p>\n

Now let\u2019s take a closer look at the medication grid for cholestyramine in Table 6.11c.<\/p>\n

Table 6.11c Cholestyramine Medication Grid[7]<\/sup><\/a><\/sup><\/p>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/th>\nPrototype\/G<\/strong>eneric<\/strong><\/th>\nNursing <\/strong>Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Bile Acid Sequestrant<\/strong><\/td>\ncholestyramine<\/a><\/td>\nMonitor the client<\/span>‘s lipid profile, liver function tests, and vitamin levels<\/p>\n

These medications should not be used in client<\/span>s with a history of bowel obstruction or in client<\/span>s with triglyceride levels greater than 500 mg\/dL<\/td>\n

Reduce LDL<\/td>\nConstipation<\/p>\n

Bloating<\/p>\n

Flatulence<\/p>\n

Abdominal discomfort<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Niacin<\/h2>\n

Mechanism of Action: <\/strong>Niacin works by inhibiting the synthesis of triglycerides and LDL cholesterol.<\/p>\n

Indications:<\/strong> Niacin is given to reduce the production of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol, while increasing the levels of high-density lipoprotein (HDL) cholesterol in the blood.<\/p>\n

Nursing Considerations: <\/strong>Nursing considerations for administration include monitoring lipid profiles, liver function tests, and blood glucose levels. Client<\/span>s should be advised to take niacin with meals to minimize adverse effects. Client<\/span>s should also be advised to report any adverse effects to their health care provider.<\/p>\n

Side Effects\/Adverse Effects: <\/strong>Adverse effects of niacin include flushing, itching, and tingling, particularly in the face, neck, and chest.<\/p>\n

Health Teaching & Health Promotion: <\/strong>Client<\/span>s should also be advised to avoid hot beverages or alcohol, as these can exacerbate flushing. Niacin can also cause liver toxicity, so liver function tests should be monitored regularly. In addition, niacin can increase blood glucose levels, so client<\/span>s with diabetes should have their blood glucose levels monitored closely. Client<\/span>s should be advised to take niacin with meals to minimize adverse effects.<\/p>\n

Now let\u2019s take a closer look at the medication grid for niacin in Table 6.11d.<\/p>\n

Table 6.11d Niacin Medication Grid[8]<\/sup><\/a><\/sup><\/p>\n\n\n\n\n
Class\/<\/strong>Subclass<\/strong><\/th>\nPrototype\/G<\/strong>eneric<\/strong><\/th>\nNursing <\/strong>Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Vitamin B3<\/strong><\/td>\nniacin<\/a><\/td>\nMonitor lipid profiles, liver function tests, and blood glucose levels<\/p>\n

Take niacin with meals to minimize adverse effects<\/p>\n

Report any adverse effects to their health care provider<\/td>\n

Reduce LDL<\/td>\nConstipation<\/p>\n

Bloating<\/p>\n

Flatulence<\/p>\n

Abdominal discomfort<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

  1. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  2. uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a> ↵<\/a><\/li>
  3. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  4. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  5. uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a> ↵<\/a><\/li>
  6. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  7. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  8. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li><\/ol><\/div>","protected":false},"author":83,"menu_order":11,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[48],"contributor":[],"license":[],"class_list":["post-282","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":238,"_links":{"self":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/users\/83"}],"version-history":[{"count":1,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/282\/revisions"}],"predecessor-version":[{"id":283,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/282\/revisions\/283"}],"part":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/238"}],"metadata":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/282\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/media?parent=282"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=282"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/contributor?post=282"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/license?post=282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}